title: Unanswered questions in evaluating rituximab efficacy: comment on the article by Merrill et al.
authors.forename: Lidia
authors.initials: L
authors.lastname: Rudnicka
authors.forename: Malgorzata
authors.initials: M
authors.lastname: Olszewska
authors.forename: Agnieszka
authors.initials: A
authors.lastname: Kardynal
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000628:therapy*; D000069283:Rituximab; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab